15 June 2023

Company Announcements Office
Australian Securities Exchange

First Two Patients Enrolled and Dosing Commenced

Vectus Biosystems Limited (Vectus or the Company) is pleased to announce that the first two patients (one at Nucleus Network, Melbourne and one at Scientia Clinical, Sydney) have been enrolled and commenced dosing in the Company's Phase Ib trial, entitled: "A Phase I/Ib, First-Time-in-Human, Single Centre, Double-Blind, Randomised, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of VB0004 Administered Orally to Healthy Volunteers; and to Patients with Mild to Moderate Hypertension with Low Cardiovascular Risk", NCT04925050.

In this double-blind placebo-controlled trial, patients with mild to moderate hypertension and at low cardiovascular risk are randomised to receive VB0004 (30mg daily) or a matching placebo capsule once daily for 28 days. When completed it is hoped that this study will provide pharmacodynamic data for VB0004.

Vectus Biosystems Limited

Karen Duggan
Chief Executive Officer and Executive Director

This Vectus announcement was authorised by the Board of Directors.

About Vectus Biosystems Limited

Vectus Biosystems Limited is developing a treatment for fibrosis and high blood pressure, which includes the treatment for three of the largest diseases in the fibrotic market, namely heart, kidney and liver diseases. Vectus successfully completed its Initial Public Offering (IPO) on the Australian Securities Exchange (ASX:VBS) and commenced trading on ASX on 23 February 2016, after raising $5.1 million. Funds from the IPO were predominantly used to develop the Company's lead compound, VB0004, which aims to treat the hardening of functional tissue and high blood pressure. Vectus has conducted a range of successful pre-clinical trials, which have shown that VB0004 slows down the advances of fibrosis, potentially repairs damaged cell tissue and reduces high blood pressure. VB0004 is now progressing through a number of important milestones, including pharmaceutical scale-up and additional toxicity studies. Following successful results, the 2019 convertible note fundraising, which have all been subsequently been converted into shares, and the 2020 and 2022 share placements and SPP, the Company has funding for its Human Phase Ib trial of VB0004, and to advance it and the other drugs in its library. Vectus' strategy is to develop and perform early validation of its drug candidates to the point where they may become commercially attractive to potential pharmaceutical partners.

The Company has also developed technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The technology, called Accugen, is owned by Vectus' wholly-owned subsidiary Accugen Pty Limited. The technology offers a time, cost and accuracy benefit compared to currently-available systems. The Company's current stage of investment in Accugen is a commercialisation programme that may include direct sales, distribution partnerships and licensing opportunities.